ABT-639

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C20H20ClF2N3O3S
Molecular Weight	455.906
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

FC1=CC=CC=C1NS(=O)(=O)C2=C(F)C=C(Cl)C(=C2)C(=O)N3CCN4CCC[C@@H]4C3

InChI

InChIKey=AGPIHNZOZNKRGT-CYBMUJFWSA-N

InChI=1S/C20H20ClF2N3O3S/c21-15-11-17(23)19(30(28,29)24-18-6-2-1-5-16(18)22)10-14(15)20(27)26-9-8-25-7-3-4-13(25)12-26/h1-2,5-6,10-11,13,24H,3-4,7-9,12H2/t13-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C20H20ClF2N3O3S
Molecular Weight	455.906
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://adisinsight.springer.com/drugs/800035078 | https://www.ncbi.nlm.nih.gov/pubmed/24726441

ABT-639 is a T-type calcium (Cav3.2) channel antagonist that was in development with AbbVie for the treatment for pain. ABT-639 is a potent and selective T-type calcium channel blocker. ABT-639 effectively reduces nociceptive and neuropathic pain in rats. ABT-639 produces robust antinociceptive activity in experimental pain models at doses that do not significantly alter psychomotor or hemodynamic function in the rat. ABT-639 blocks recombinant human T-type (Cav3.2) Ca2+ channels in a voltage-dependent fashion (IC50=2 uM) and attenuates low voltage-activated (LVA) currents in rat DRG neurons (IC50=8 uM). ABT-639 was significantly less active at other Ca²⁺ channels (e.g. Ca(v)1.2 and Ca(v)2.2) (IC₅₀ > 30 uM). ABT-639 has high oral bioavailability (%F = 73), low protein binding (88.9%) and a low brain:plasma ratio (0.05:1) in rodents.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Voltage-gated T-type calcium channel alpha-1H subunit 7 Target ID: CHEMBL1859 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24726441	Blocker 555		2.3 µM [IC50]

PubMed

Title	Date	PubMed
A Randomized, Double-Blind, Placebo-Controlled, Crossover Study of the T-Type Calcium Channel Blocker ABT-639 in an Intradermal Capsaicin Experimental Pain Model in Healthy Adults.	2016-03	26814294
Optimization of ADME Properties for Sulfonamides Leading to the Discovery of a T-Type Calcium Channel Blocker, ABT-639.	2015-06-11	26101566
A peripherally acting, selective T-type calcium channel blocker, ABT-639, effectively reduces nociceptive and neuropathic pain in rats.	2014-06-15	24726441

Patents

Sample Use Guides

In Vivo Use Guide

Healthy adult males (aged 21 to 55 years) were randomly assigned to receive single oral doses of ABT-639, pregabalin, and placebo. A single 100-mg dose of ABT-639 had no effect on experimental pain induced by intradermal capsaicin injection.

Route of Administration: Oral

In Vitro Use Guide

ABT-639 blocks recombinant human T-type (Cav3.2) Ca2+ channels in a voltage-dependent fashion (IC50=2 uM) and attenuates low voltage-activated (LVA) currents in rat DRG neurons (IC50=8 uM). ABT-639 is significantly less active at other Ca2+ channels (e.g. Cav1.2 and Cav2.2) (IC50>30 uM).

Substance Class	Chemical Created by `admin` on `Mon Mar 31 21:54:38 GMT 2025` Edited by `admin` on `Mon Mar 31 21:54:38 GMT 2025`
Record UNII	0G7D0CQ88I
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ABT-639

Common Name

English

ABT-639 FREE BASE

Preferred Name

English

BENZENESULFONAMIDE, 4-CHLORO-2-FLUORO-N-(2-FLUOROPHENYL)-5-(((8AR)-HEXAHYDROPYRROLO(1,2-A)PYRAZIN-2(1H)-YL)CARBONYL)-

Systematic Name

English

Code System Code Type Description

FDA UNII

0G7D0CQ88I